[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@Bullstkpicks Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1658827178879119365.png) @Bullstkpicks Bull Stock Picks

Bull Stock Picks posts on X about $inv, $inbx, command, $3b the most. They currently have XXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::1658827178879119365/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1658827178879119365/c:line/m:interactions.svg)

- X Week XXXXX -XX%
- X Month XXXXXX +47%
- X Months XXXXXXX +23%
- X Year XXXXXXX +212%

### Mentions: X [#](/creator/twitter::1658827178879119365/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1658827178879119365/c:line/m:posts_active.svg)

- X Month XX +39%
- X Months XXX +26%
- X Year XXX +259%

### Followers: XXX [#](/creator/twitter::1658827178879119365/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1658827178879119365/c:line/m:followers.svg)

- X Week XXX +1.90%
- X Month XXX +3.80%
- X Months XXX +50%
- X Year XXX +128%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::1658827178879119365/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1658827178879119365/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[cryptocurrencies](/list/cryptocurrencies)  [finance](/list/finance)  [currencies](/list/currencies)  [stocks](/list/stocks)  [technology brands](/list/technology-brands) 

**Social topic influence**
[$inv](/topic/$inv) #25, [$inbx](/topic/$inbx) #3, [command](/topic/command) #787, [$3b](/topic/$3b) #20, [if you](/topic/if-you), [$25b](/topic/$25b), [$eose](/topic/$eose), [future](/topic/future), [ton](/topic/ton), [ceo](/topic/ceo)

**Top accounts mentioned or mentioned by**
[@richardxroe](/creator/undefined) [@xtimes1](/creator/undefined) [@domocapital](/creator/undefined) [@bertgilfoyle](/creator/undefined) [@bleacherbum23](/creator/undefined) [@mcinnesdanny](/creator/undefined) [@rocketpenguin75](/creator/undefined) [@joceyreyes209](/creator/undefined) [@eenlien](/creator/undefined) [@enovixbatteries](/creator/undefined) [@crowdturtle](/creator/undefined) [@2percentisfair](/creator/undefined) [@rabbitholegoe](/creator/undefined) [@mrnotadvice](/creator/undefined) [@fourierf](/creator/undefined) [@leadlagreport](/creator/undefined) [@spenbaker](/creator/undefined) [@gmcthoughts](/creator/undefined) [@foldnow1984](/creator/undefined) [@xebitda](/creator/undefined)

**Top assets mentioned**
[Inverse Finance (INV)](/topic/$inv) [Eos Energy Enterprises, Inc. (EOSE)](/topic/$eose)
### Top Social Posts
Top posts by engagements in the last XX hours

"@pick1998_2 @AaronRosenblum5 💯 agree on $INBX sale of XXX for $125-$150 plus outside chance XXX hits. Data within the next X weeks"  
[X Link](https://x.com/Bullstkpicks/status/1996522089357214154)  2025-12-04T10:08Z XXX followers, XXX engagements


"@Phoenix3million @A_May_MD $INBX is undervalued in my opinion. They are currently taking XXX to market and I estimate $125-$150 in sale price per share for that drug alone. Likely announcement in late q1"  
[X Link](https://x.com/Bullstkpicks/status/1998447775327920181)  2025-12-09T17:40Z XXX followers, XXX engagements


"$INBX The Most Mispriced Oncology Asset in Small-Cap Biotech Deep Dive on INBRX-109 Value: Most people still think INBRX-109 is a tiny rare-disease drug worth a few hundred million. That thesis is now completely wrong in my opinion: With the new CRC & Ewing data INBRX-109 looks like a multi-indication first-in-class DR5 agonist that could command a $2.5B$3B sale price on its own. Heres is my opinion based on discussion with managment and several oncology doctors: X. Registrational Data: Overlooked Strength - PFS doubled in conventional chondrosarcoma (5.52 vs XXXX months) - HR = XXXXX p"  
[X Link](https://x.com/Bullstkpicks/status/1994842560007655848)  2025-11-29T18:55Z XXX followers, XXX engagements


"@x_times_1 Great list have read most. If you want a good market based on read XXX bagger applicable to $EOSE & $INV"  
[X Link](https://x.com/Bullstkpicks/status/1994822513164234893)  2025-11-29T17:35Z XXX followers, XXX engagements


"@x_times_1 $INV just bought 15000 more shares"  
[X Link](https://x.com/Bullstkpicks/status/1995506237237273038)  2025-12-01T14:52Z XXX followers, XXX engagements


"$INV - the future of cooling. The price now is not even remotely close to the value of their holding in Accelsius (44% roughly). Should be $XX min. currently IMHO"  
[X Link](https://x.com/Bullstkpicks/status/1996352337926111343)  2025-12-03T22:54Z XXX followers, XXX engagements


"The company will be sold by end of q1 and they will do a spinCo into a privately owned company for remaining small assets. It is not hard to know these things if you just do some DD and talk with managment and some in the medical community that deal in this area. I bought a lot in the 20s and a ton after the data came out around $50"  
[X Link](https://x.com/Bullstkpicks/status/1998450191079178357)  2025-12-09T17:50Z XXX followers, XXX engagements


"$INV incredible article by Accelsius CEO taking about their next generation cooling technology. New data centers and existing ones (with their ability to convert single phase water to their tech) is going to explode. The more I look into it the more I feel Accelsius could be a $10B+ company in a few years. $INV is the only way for retail investors to be able to buy into Accelsius with their XX% ownership"  
[X Link](https://x.com/Bullstkpicks/status/1997322545888972959)  2025-12-06T15:09Z XXX followers, XXX engagements


"It's really not that hard to see. I feed all the data into to ChatGPT and here is the summary: 🔥 INBX The Market Is Mispricing INBRX-109 by Billions. Heres the Real Valuation Math. Most people still treat INBRX-109 as a tiny orphan drug worth a few hundred million. Thats not what the clinical data or the M&A market says. In reality XXX alone could command $2B$3B in a sale today. Heres the breakdown 👇 X Annual Revenue Potential for INBRX-109 (Based on Realistic Assumptions) A. Chondrosarcoma (core label) 15002000 U.S. cases per year XX% unresectable/metastatic 300400 treatable patients"  
[X Link](https://x.com/Bullstkpicks/status/1999104386857906242)  2025-12-11T13:10Z XXX followers, XXX engagements